A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Alemtuzumab
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Recurrence
Retreatment
Treatment Outcome
Vidarabine

authors with profiles

Wendy Stock